Merck (MRK) has entered into an exclusive global licensing agreement with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D (ON) inhibitor.

Under the agreement, SciBrunch granted Merck exclusive worldwide rights to develop, manufacture, and commercialize SPR2015. Merck will pay $400M upfront, with SciBrunch eligible for